Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial

Indian Pediatr. 2015 Oct;52(10):847-51. doi: 10.1007/s13312-015-0730-y.

Abstract

Objective: To evaluate the efficacy and safety of Drotaverine hydrochroride in children with recurrent abdominal pain.

Design: Double blind, randomized placebo-controlled trial.

Setting: Pediatric Gastroenterology clinic of a teaching hospital.

Participants: 132 children (age 4-12 y) with recurrent abdominal pain (Apley Criteria) randomized to receivedrotaverine (n=66) or placebo (n=66) orally.

Intervention: Children between 4-6 years of age received 10 mL syrup orally (20 mg drotaverine hydrochloride or placebo) thrice daily for 4 weeks while children >6 years of age received one tablet orally (40 mg drotaverine hydrochloride or placebo) thrice daily for 4 weeks.

Outcome measures: Primary: Number of episodes of pain during 4 weeks of use of drug/placebo and number of pain-free days. Secondary: Number of school days missed during the study period, parental satisfaction (on a Likert scale), and occurrence of solicited adverse effects.

Results: Reduction in number of episodes of abdominal pain [mean (SD) number of episodes 10.3 (14) vs 21.6 (32.4); P=0.01] and lesser school absence [mean (SD) number of school days missed 0.25 (0.85) vs 0.71 (1.59); P=0.05] was noticed in children receiving drotaverine in comparison to those who received placebo. The number of pain-free days, were comparable in two groups [17.4 (8.2) vs 15.6 (8.7); P=0.23]. Significant improvement in parental satisfaction score was noticed on Likert scale by estimation of mood, activity, alertness, comfort and fluid intake. Frequency of adverse events during follow-up period was comparable between children receiving drotaverine or placebo (46.9% vs 46.7%; P=0.98).

Conclusion: Drotaverine hydrochloride is an effective and safe pharmaceutical agent in the management of recurrent abdominal pain in children.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Pain / drug therapy*
  • Absenteeism
  • Administration, Oral
  • Child
  • Child, Preschool
  • Chronic Pain / drug therapy*
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Gastrointestinal Diseases / drug therapy*
  • Humans
  • India
  • Male
  • Papaverine / analogs & derivatives*
  • Papaverine / therapeutic use
  • Treatment Outcome

Substances

  • drotaverin
  • Papaverine